Description:
Nepicastat hydrochloride (SYN117, RS-25560-197) is an inhibitor of dopamine beta-hydroxylase that catalyzes the conversion of dopamine to norepinephrine. Nepicastat hydrochloride shows the selective and concentration-dependent inhibition effects on bovine and human dopamine-beta-hydroxylase activity in vitro. In vivo, Nepicastat hydrochloride increases dopamine content and dopamine/noradrenaline ratio in a dose-dependent manner. Nepicastat hydrochloride also produces the similar effects on noradrenaline, dopamine and dopamine/noradrenaline ratio in tissues and plasma of beagle dogs. Nepicastat is currently in Phase II clinical trials in patients with Posttraumatic Stress Disorder.
- Molecular Weight: 331.81
- Molecular Formula: C14H16ClF2N3S
Purity: >98%
Canonical SMILES:
C1CC2=C(C=C(C=C2CC1N3C(=CNC3=S)CN)F)F.Cl
InChI:
InChI=1S/C14H15F2N3S.ClH/c15-9-3-8-4-10(1-2-12(8)13(16)5-9)19-11(6-17)7-18-14(19)20;/h3,5,7,10H,1-2,4,6,17H2,(H,18,20);1H/t10-;/m0./s1
InChIKey: DIPDUAJWNBEVOY-PPHPATTJSA-N
- Solubility: DMSO: soluble10mg/mL, clear
- Appearance: solid powder
- Application: Nepicastat is currently in Phase II clinical trials in patients with Posttraumatic Stress Disorder.
Synonyms:
N6022; N 6022; N-6022; Nepicastat hydrochloride; (S)-5-(aminomethyl)-1-(5,7-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)-1H-imidazole-2(3H)-thione hydrochloride; Nepicastat (hydrochloride); UNII-3WK068D17I
More details are to be found on supplier website
